As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Taken alongside Prolia/Xgeva, the brands account for well over 40% of Amgen's current revenues. Other companies working on biosimilar versions of denosumab include Samsung Bioepis, Celltrion, and ...

“Denosumab helps maintain bone strength ... of this medicine for people with osteoporosis is that it’s an injection they can give to themselves or can be given by a caregiver.

Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among patients on dialysis. Cardiovascular risk was 36% higher with denosumab. Among adults ...

and Osenvelt (120 mg solution for injection in vial) have been recommended for approval for all indications of the reference products Prolia ® and Xgeva ®, respectively. The positive CHMP ...